Recro Pharma Inc (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $10.07, for a total transaction of $2,014,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Healthcare Master Fun Broadfin also recently made the following trade(s):
- On Thursday, December 21st, Healthcare Master Fun Broadfin sold 76,000 shares of Recro Pharma stock. The stock was sold at an average price of $9.87, for a total transaction of $750,120.00.
REPH traded down $0.39 during trading on Friday, reaching $10.19. 131,827 shares of the stock were exchanged, compared to its average volume of 263,469. The company has a market cap of $198.69, a price-to-earnings ratio of -5.12 and a beta of -0.74. Recro Pharma Inc has a twelve month low of $5.81 and a twelve month high of $12.23. The company has a current ratio of 1.75, a quick ratio of 1.55 and a debt-to-equity ratio of 1.86.
Recro Pharma (NASDAQ:REPH) last issued its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.85) by $0.22. The business had revenue of $19.04 million for the quarter, compared to the consensus estimate of $12.88 million. Recro Pharma had a negative net margin of 69.61% and a negative return on equity of 75.97%. research analysts forecast that Recro Pharma Inc will post -3.02 earnings per share for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. JT Stratford LLC increased its holdings in Recro Pharma by 7.8% during the fourth quarter. JT Stratford LLC now owns 112,265 shares of the specialty pharmaceutical company’s stock worth $1,038,000 after buying an additional 8,120 shares during the last quarter. Lyon Street Capital LLC bought a new position in Recro Pharma during the fourth quarter worth $3,362,000. Two Sigma Investments LP bought a new position in Recro Pharma during the fourth quarter worth $164,000. Deutsche Bank AG boosted its position in Recro Pharma by 141.6% during the fourth quarter. Deutsche Bank AG now owns 30,446 shares of the specialty pharmaceutical company’s stock worth $281,000 after purchasing an additional 17,845 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Recro Pharma by 23.4% during the fourth quarter. Renaissance Technologies LLC now owns 122,000 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after purchasing an additional 23,100 shares during the period. Institutional investors and hedge funds own 57.85% of the company’s stock.
A number of analysts have recently issued reports on REPH shares. CIBC started coverage on shares of Recro Pharma in a report on Wednesday, February 14th. They issued an “outperform” rating and a $19.00 price objective on the stock. Zacks Investment Research upgraded shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, March 21st. Oppenheimer started coverage on shares of Recro Pharma in a report on Tuesday, February 13th. They issued an “outperform” rating and a $19.00 price objective on the stock. UBS started coverage on shares of Recro Pharma in a report on Tuesday, February 13th. They issued an “outperform” rating on the stock. Finally, ValuEngine upgraded shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Recro Pharma currently has an average rating of “Buy” and an average target price of $14.21.
WARNING: “Recro Pharma Inc (NASDAQ:REPH) Major Shareholder Healthcare Master Fun Broadfin Sells 200,000 Shares” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/healthcare-master-fun-broadfin-sells-200000-shares-of-recro-pharma-inc-reph-stock.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.